• Explore /
  • Poster
  • / TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

Abstract Video & Slides Poster

Authors

null

Johann S. De Bono

The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

Johann S. De Bono , Niven Mehra , Celestia S. Higano , Fred Saad , Consuelo Buttigliero , Inge M. van Oort , Marielena Mata , Hsiang-Chun Chen , Cynthia G. Healy , M. Luisa Paccagnella , Akos Czibere , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03148795

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5566)

DOI

10.1200/JCO.2020.38.15_suppl.5566

Abstract #

5566

Poster Bd #

147

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Niven Mehra

First Author: Xiao X. Wei

First Author: Neeraj Agarwal